⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AZN News
AstraZeneca PLC
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
globenewswire.com
AMGN
CSL
NVS
REGN
SNY
UCB
AZN
IONS
TEVA
Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
globenewswire.com
INBX
LLY
PFE
NVS
BMY
EXEL
JNJ
AZN
JAZZ
TLRY
Alveus Therapeutics Strengthens Executive Leadership Team, Opens Boston office
globenewswire.com
GILD
AZN
MRK
Enhertu ® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
businesswire.com
AZN
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
globenewswire.com
HCM
AZN
Specialty Pharmaceuticals Market (2026-2031) - Rising Prevalence of Chronic and Rare Diseases Drives Growth
globenewswire.com
ABBV
AMGN
AZN
BIIB
BMRA
BMY
JNJ
MRK
NVS
PFE
REGN
SNY
TEVA
VRTX
Cytotoxic Drugs Market Report Now Available — Forecasts Market Growth from $16.21B (2026) to $21.06B by 2031, Profiling Pfizer, Roche, Novartis, AstraZeneca, Sanofi, and 15 Other Key Players
globenewswire.com
PFE
NVS
AZN
SNY
LLY
JNJ
MRK
AMGN
BIIB
GILD
BMY
ABBV
XRAY
VTRS
TEVA
SUN
Sonar Launches SonarQube Hunter Agent to Catch Logic-based Security Flaws
prnewswire.com
NVDA
NOW
GS
AZN
F
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
businesswire.com
AZN
DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
businesswire.com
AZN
MRK